237 related articles for article (PubMed ID: 29518205)
1. The combination of ionizing radiation and proteasomal inhibition by bortezomib enhances the expression of NKG2D ligands in multiple myeloma cells.
Lee YS; Heo W; Nam J; Jeung YH; Bae J
J Radiat Res; 2018 May; 59(3):245-252. PubMed ID: 29518205
[TBL] [Abstract][Full Text] [Related]
2. Low-dose bortezomib increases the expression of NKG2D and DNAM-1 ligands and enhances induced NK and γδ T cell-mediated lysis in multiple myeloma.
Niu C; Jin H; Li M; Zhu S; Zhou L; Jin F; Zhou Y; Xu D; Xu J; Zhao L; Hao S; Li W; Cui J
Oncotarget; 2017 Jan; 8(4):5954-5964. PubMed ID: 27992381
[TBL] [Abstract][Full Text] [Related]
3. Synergistic enhancement of NK cell-mediated cytotoxicity by combination of histone deacetylase inhibitor and ionizing radiation.
Son CH; Keum JH; Yang K; Nam J; Kim MJ; Kim SH; Kang CD; Oh SO; Kim CD; Park YS; Bae J
Radiat Oncol; 2014 Feb; 9():49. PubMed ID: 24512718
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of bromodomain and extra-terminal (BET) proteins increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of cMYC-IRF4-miR-125b interplay.
Abruzzese MP; Bilotta MT; Fionda C; Zingoni A; Soriani A; Vulpis E; Borrelli C; Zitti B; Petrucci MT; Ricciardi MR; Molfetta R; Paolini R; Santoni A; Cippitelli M
J Hematol Oncol; 2016 Dec; 9(1):134. PubMed ID: 27903272
[TBL] [Abstract][Full Text] [Related]
5. Bortezomib enhances cytotoxicity of ex vivo-expanded gamma delta T cells against acute myeloid leukemia and T-cell acute lymphoblastic leukemia.
Story JY; Zoine JT; Burnham RE; Hamilton JAG; Spencer HT; Doering CB; Raikar SS
Cytotherapy; 2021 Jan; 23(1):12-24. PubMed ID: 33168453
[TBL] [Abstract][Full Text] [Related]
6. Increase of NKG2D ligands and sensitivity to NK cell-mediated cytotoxicity of tumor cells by heat shock and ionizing radiation.
Kim JY; Son YO; Park SW; Bae JH; Chung JS; Kim HH; Chung BS; Kim SH; Kang CD
Exp Mol Med; 2006 Oct; 38(5):474-84. PubMed ID: 17079863
[TBL] [Abstract][Full Text] [Related]
7. Radiation-induced matrix metalloproteinases limit natural killer cell-mediated anticancer immunity in NCI-H23 lung cancer cells.
Heo W; Lee YS; Son CH; Yang K; Park YS; Bae J
Mol Med Rep; 2015 Mar; 11(3):1800-6. PubMed ID: 25385045
[TBL] [Abstract][Full Text] [Related]
8. Immunomodulatory effect of NEDD8-activating enzyme inhibition in Multiple Myeloma: upregulation of NKG2D ligands and sensitization to Natural Killer cell recognition.
Petillo S; Capuano C; Molfetta R; Fionda C; Mekhloufi A; Pighi C; Antonangeli F; Zingoni A; Soriani A; Petrucci MT; Galandrini R; Paolini R; Santoni A; Cippitelli M
Cell Death Dis; 2021 Sep; 12(9):836. PubMed ID: 34482362
[TBL] [Abstract][Full Text] [Related]
9. The proteasome inhibitor bortezomib disrupts tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression and natural killer (NK) cell killing of TRAIL receptor-positive multiple myeloma cells.
Feng X; Yan J; Wang Y; Zierath JR; Nordenskjöld M; Henter JI; Fadeel B; Zheng C
Mol Immunol; 2010 Aug; 47(14):2388-96. PubMed ID: 20542572
[TBL] [Abstract][Full Text] [Related]
10. Quercetin enhances susceptibility to NK cell-mediated lysis of tumor cells through induction of NKG2D ligands and suppression of HSP70.
Bae JH; Kim JY; Kim MJ; Chang SH; Park YS; Son CH; Park SJ; Chung JS; Lee EY; Kim SH; Kang CD
J Immunother; 2010 May; 33(4):391-401. PubMed ID: 20386467
[TBL] [Abstract][Full Text] [Related]
11. Combination Treatment with Sublethal Ionizing Radiation and the Proteasome Inhibitor, Bortezomib, Enhances Death-Receptor Mediated Apoptosis and Anti-Tumor Immune Attack.
Cacan E; Spring AM; Kumari A; Greer SF; Garnett-Benson C
Int J Mol Sci; 2015 Dec; 16(12):30405-21. PubMed ID: 26703577
[TBL] [Abstract][Full Text] [Related]
12. Induction of NKG2D ligands and subsequent enhancement of NK cell-mediated lysis of cancer cells by arsenic trioxide.
Kim JY; Bae JH; Lee SH; Lee EY; Chung BS; Kim SH; Kang CD
J Immunother; 2008 Jun; 31(5):475-86. PubMed ID: 18463537
[TBL] [Abstract][Full Text] [Related]
13. Genotoxic Stress Induces Senescence-Associated ADAM10-Dependent Release of NKG2D MIC Ligands in Multiple Myeloma Cells.
Zingoni A; Cecere F; Vulpis E; Fionda C; Molfetta R; Soriani A; Petrucci MT; Ricciardi MR; Fuerst D; Amendola MG; Mytilineos J; Cerboni C; Paolini R; Cippitelli M; Santoni A
J Immunol; 2015 Jul; 195(2):736-48. PubMed ID: 26071561
[TBL] [Abstract][Full Text] [Related]
14. NKG2D and DNAM-1 Ligands: Molecular Targets for NK Cell-Mediated Immunotherapeutic Intervention in Multiple Myeloma.
Fionda C; Soriani A; Zingoni A; Santoni A; Cippitelli M
Biomed Res Int; 2015; 2015():178698. PubMed ID: 26161387
[TBL] [Abstract][Full Text] [Related]
15. [Mechanism of action and determinants of sensitivity to the proteasome inhibitor bortezomib in multiple myeloma therapy].
Ri M
Rinsho Ketsueki; 2016 May; 57(5):537-45. PubMed ID: 27263777
[TBL] [Abstract][Full Text] [Related]
16. Heat shock protein-90 inhibitors increase MHC class I-related chain A and B ligand expression on multiple myeloma cells and their ability to trigger NK cell degranulation.
Fionda C; Soriani A; Malgarini G; Iannitto ML; Santoni A; Cippitelli M
J Immunol; 2009 Oct; 183(7):4385-94. PubMed ID: 19748980
[TBL] [Abstract][Full Text] [Related]
17. Induction of NKG2D ligands and increased sensitivity of tumor cells to NK cell-mediated cytotoxicity by hematoporphyrin-based photodynamic therapy.
Park MJ; Bae JH; Chung JS; Kim SH; Kang CD
Immunol Invest; 2011; 40(4):367-82. PubMed ID: 21314289
[TBL] [Abstract][Full Text] [Related]
18. The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cell-mediated killing of myeloma cells.
El-Sherbiny YM; Meade JL; Holmes TD; McGonagle D; Mackie SL; Morgan AW; Cook G; Feyler S; Richards SJ; Davies FE; Morgan GJ; Cook GP
Cancer Res; 2007 Sep; 67(18):8444-9. PubMed ID: 17875681
[TBL] [Abstract][Full Text] [Related]
19. Human NK cells are alerted to induction of p53 in cancer cells by upregulation of the NKG2D ligands ULBP1 and ULBP2.
Textor S; Fiegler N; Arnold A; Porgador A; Hofmann TG; Cerwenka A
Cancer Res; 2011 Sep; 71(18):5998-6009. PubMed ID: 21764762
[TBL] [Abstract][Full Text] [Related]
20. Proteasome regulation of ULBP1 transcription.
Butler JE; Moore MB; Presnell SR; Chan HW; Chalupny NJ; Lutz CT
J Immunol; 2009 May; 182(10):6600-9. PubMed ID: 19414815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]